Bruno Bockorny MD FACP (@brunobockorny) 's Twitter Profile
Bruno Bockorny MD FACP

@brunobockorny

Phase 1 Oncology | Drug Development | GI oncology @BIDMCHealth, Assistant Professor at Harvard @HarvardMed.

ID: 788922619005403137

linkhttps://www.dfhcc.harvard.edu/insider/member-detail/member/bruno-bockorny-md/ calendar_today20-10-2016 01:59:44

695 Tweet

1,1K Followers

1,1K Following

Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

Deleted this tweet due to unexpected amount of likes/retweets from bots. As discussed by many, exciting to see this data but we need to do better overall in this disease site and need a bigger study with adequate control arm. #ONCtwitter #lcsm #SmallCellLungCancer #MedEd

Deleted this tweet due to unexpected amount of likes/retweets from bots. As discussed by many, exciting to see this data but we need to do better overall in this disease site and need a bigger study with adequate control arm.

#ONCtwitter #lcsm #SmallCellLungCancer #MedEd
IMG Oncologists (@img_oncologists) 's Twitter Profile Photo

🎉 Get ready for #ASCO24🚀 Join the IMG Oncology Community of Practice (CoP) during #ASCO24 🌟 Scan our QR codes to invite your friends and connect with the #IMG Oncology Community! Let’s grow together💫 ASCO ASCO TECAG OncoAlert

🎉 Get ready for #ASCO24🚀

Join the IMG Oncology Community of Practice (CoP) during #ASCO24 🌟

Scan our QR codes to invite your friends and connect with the #IMG Oncology Community! 
Let’s grow together💫

<a href="/ASCO/">ASCO</a> <a href="/ASCOTECAG/">ASCO TECAG</a> <a href="/OncoAlert/">OncoAlert</a>
Fabrizio Romano (@fabrizioromano) 's Twitter Profile Photo

⚪️🇧🇷 Two Champions League finals, two goals. Vinicius Júnior scores his 24th (!) goal of the season for Real Madrid. 🏆⏳

⚪️🇧🇷 Two Champions League finals, two goals.

Vinicius Júnior scores his 24th (!) goal of the season for Real Madrid.

🏆⏳
BIDMC Cancer Center (@bidmc_cancerctr) 's Twitter Profile Photo

🔥Hot off the press📰Andrea Bullock, MD BIDMC Department of Medicine et al Nature Medicine: "Botensilimab Plus Balstilimab in R/R MSS mCRC: A Phase 1 Trial". ▶️BOT+BAL combo: manageable safety profile + encouraging clinical activity #ColorectalCancer #ClinicalTrial #CancerResearch #MedTwitter

🔥Hot off the press📰Andrea Bullock, MD <a href="/BIDMC_Medicine/">BIDMC Department of Medicine</a> et al <a href="/NatureMedicine/">Nature Medicine</a>: "Botensilimab Plus Balstilimab in R/R MSS mCRC: A Phase 1 Trial".
▶️BOT+BAL combo: manageable safety profile + encouraging clinical activity #ColorectalCancer #ClinicalTrial #CancerResearch #MedTwitter
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

CD40 agonist mitazalimab with mFOLFIRINOX in mPDAC #ESMOGI24 🔎OPTIMIZE-1 phase Ib/II study ✅study: ORR 42%, mDoR: 12.6 mo 👉mPFS: 7.7 mo, mOS: 14.9 mo 🧐promising data, phs-3 on the way.. #ESMOAmbassadors ESMO - Eur. Oncology

CD40 agonist mitazalimab with mFOLFIRINOX in mPDAC #ESMOGI24 
🔎OPTIMIZE-1 phase Ib/II study
✅study: ORR 42%, mDoR: 12.6 mo
👉mPFS: 7.7 mo, mOS: 14.9 mo
🧐promising data, phs-3 on the way..
#ESMOAmbassadors <a href="/myESMO/">ESMO - Eur. Oncology</a>
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

Liver transplantation + CTx vs CTx in unresectable CRC liver metastases 🔎TransMet randomised trial The Lancet doi.org/10.1016/S0140-… 👉5-yr OS: 56.6 vs 12.6% 👉Recurrence after LTx: 72% 🧐Impressive study, impressive results ❗️LTx valid option in highly selected pts ESMO - Eur. Oncology

Liver transplantation + CTx vs CTx  in unresectable CRC liver metastases 
🔎TransMet randomised trial
<a href="/TheLancet/">The Lancet</a> 
doi.org/10.1016/S0140-…
👉5-yr OS: 56.6 vs 12.6%
👉Recurrence after LTx: 72%
🧐Impressive study, impressive results
❗️LTx valid option in highly selected pts
<a href="/myESMO/">ESMO - Eur. Oncology</a>
BIDMC Cancer Center (@bidmc_cancerctr) 's Twitter Profile Photo

We are incredibly proud of our Rectal Cancer team and this outstanding achievement, which serves as a testament to our outstanding dedication towards patient care 🎉

Anirban Maitra (@aiims1742) 's Twitter Profile Photo

New Clinical Cancer Research paper from Manuel Hidalgo 🇪🇸 🇺🇸 Bruno Bockorny MD FACP Senthil K Muthuswamy & colleagues: A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial aacrjournals.org/clincancerres/… Important trial that shows that technology

New <a href="/CCR_AACR/">Clinical Cancer Research</a> paper from <a href="/DrMhidalgo/">Manuel Hidalgo 🇪🇸 🇺🇸</a> <a href="/BrunoBockorny/">Bruno Bockorny MD FACP</a> <a href="/3dorganoid/">Senthil K Muthuswamy</a> &amp; colleagues:
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial
aacrjournals.org/clincancerres/…
Important trial that shows that technology
Bruno Bockorny MD FACP (@brunobockorny) 's Twitter Profile Photo

A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer pubmed.ncbi.nlm.nih.gov/39693144/